SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advance Remediation strategies following the voluntary recall of BREXAFEMME® and the MARIO study clinical hold are …